Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01431287




Registration number
NCT01431287
Ethics application status
Date submitted
8/09/2011
Date registered
9/09/2011
Date last updated
16/07/2015

Titles & IDs
Public title
Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)
Scientific title
A Randomised, Double-blind, Parallel Group Study to Assess the Efficacy and Safety of 52 Weeks of Once Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (2.5 µg / 5 µg; 5 µg / 5 µg) (Delivered by the Respimat® Inhaler) Compared With the Individual Components (2.5 µg and 5 µg Tiotropium, 5 µg Olodaterol) (Delivered by the Respimat® Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD) [TOnado TM 2]
Secondary ID [1] 0 0
2009-010669-22
Secondary ID [2] 0 0
1237.6
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Condition category
Condition code
Respiratory 0 0 0 0
Chronic obstructive pulmonary disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - tiotropium + olodaterol
Treatment: Drugs - tiotropium + olodaterol
Treatment: Drugs - tiotropium
Treatment: Drugs - tiotropium
Treatment: Drugs - olodaterol
Treatment: Devices - Respimat

Experimental: tiotropium+olodaterol high dose FDC - Once daily 2 puffs solution for inhalation Respimat

Experimental: tiotropium+olodaterol low dose FDC - Once daily 2 puffs solution for inhalation Respimat

Active Comparator: olodaterol - Once daily 2 puffs solution for inhalation Respimat

Active Comparator: tiotropium low dose - Once daily 2 puffs solution for inhalation Respimat

Active Comparator: tiotropium high dose - Once daily 2 puffs solution for inhalation Respimat


Treatment: Drugs: tiotropium + olodaterol
fixed dose combination

Treatment: Drugs: tiotropium + olodaterol
fixed dose combination

Treatment: Drugs: tiotropium
low dose or high dose

Treatment: Drugs: tiotropium
low dose or high dose

Treatment: Drugs: olodaterol
one dose only

Treatment: Devices: Respimat
Respimat inhaler
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) (0-3h) Response on Day 169
Timepoint [1] 0 0
1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 169
Primary outcome [2] 0 0
Trough FEV1 Response on Day 170
Timepoint [2] 0 0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 23 h and at 23 h 50 min after inhalation of study medication on Day 170
Primary outcome [3] 0 0
Saint George's Respiratory Questionnaire (SGRQ) Total Score on Day 169 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274).
Timepoint [3] 0 0
Day 169
Secondary outcome [1] 0 0
Mahler Transitional Dyspnoea Index (TDI) Focal Score on Day 169 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)
Timepoint [1] 0 0
Day 169
Secondary outcome [2] 0 0
FEV1 AUC(0-3h) Response on Day 1
Timepoint [2] 0 0
1 hour (h) and 10 minutes (min) prior to dose to 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on the first day of randomized treatment
Secondary outcome [3] 0 0
FEV1 AUC(0-3h) Response on Day 85
Timepoint [3] 0 0
1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 85 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 85
Secondary outcome [4] 0 0
FEV1 AUC(0-3h) Response on Day 365
Timepoint [4] 0 0
1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 365 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 365
Secondary outcome [5] 0 0
Trough FEV1 Response on Day 15
Timepoint [5] 0 0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 10 min pre-dose on day 15
Secondary outcome [6] 0 0
Trough FEV1 Response on Day 43
Timepoint [6] 0 0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 10 min pre-dose on day 43
Secondary outcome [7] 0 0
Trough FEV1 Response on Day 85
Timepoint [7] 0 0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 1hr and 10 min pre-dose on day 85
Secondary outcome [8] 0 0
Trough FEV1 Response on Day 169
Timepoint [8] 0 0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 1hr and 10 min pre-dose on day 169
Secondary outcome [9] 0 0
Trough FEV1 Response on Day 365
Timepoint [9] 0 0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 1 hr and 10 min pre-dose on day 365
Secondary outcome [10] 0 0
Forced Vital Capacity (FVC) AUC(0-3h) Response on Day 1
Timepoint [10] 0 0
1 hour (h) and 10 minutes (min) prior to dose to 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on the first day of randomized treatment
Secondary outcome [11] 0 0
Forced Vital Capacity (FVC) AUC(0-3h) Response on Day 85
Timepoint [11] 0 0
1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 85 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 85
Secondary outcome [12] 0 0
Forced Vital Capacity (FVC) AUC(0-3h) Response on Day 169
Timepoint [12] 0 0
1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 169
Secondary outcome [13] 0 0
Forced Vital Capacity (FVC) AUC(0-3h) Response on Day 365
Timepoint [13] 0 0
1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 365 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 365
Secondary outcome [14] 0 0
Trough FVC Response on Day 15
Timepoint [14] 0 0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 10 min pre-dose on day 15
Secondary outcome [15] 0 0
Trough FVC Response on Day 43
Timepoint [15] 0 0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 10 min pre-dose on day 43
Secondary outcome [16] 0 0
Trough FVC Response on Day 85
Timepoint [16] 0 0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and on day 85
Secondary outcome [17] 0 0
Trough FVC Response on Day 170
Timepoint [17] 0 0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 23h and at 23h 50 min after inhalation of study medication on day 170
Secondary outcome [18] 0 0
Trough FVC Response on Day 365
Timepoint [18] 0 0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and on day 365
Secondary outcome [19] 0 0
FEV1 AUC(0-12h) Response in Sub-set of Patients With 12-hour Pulmonary Function Test (PFT) on Day 169 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)
Timepoint [19] 0 0
1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h post-dose on Day 169
Secondary outcome [20] 0 0
FEV1 AUC(0-24h) Response in Sub-set of Patients With 12-hour PFTs on Day 169 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)
Timepoint [20] 0 0
1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 23 h, 23 h and 50 min post-dose on Day 169
Secondary outcome [21] 0 0
FVC AUC(0-12h) Response in Sub-set of Patients With 12-hour PFTs on Day 169 From Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)
Timepoint [21] 0 0
1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h post-dose on Day 169
Secondary outcome [22] 0 0
FVC AUC(0-24h) Response in Sub-set of Patients With 12-hour PFTs on Day 169 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)
Timepoint [22] 0 0
1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 23 h, 23 h and 50 min post-dose on Day 169
Secondary outcome [23] 0 0
Saint George's Respiratory Questionnaire (SGRQ) Total Score on Day 85 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)
Timepoint [23] 0 0
Day 85
Secondary outcome [24] 0 0
Saint George's Respiratory Questionnaire (SGRQ) Total Score on Day 365 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)
Timepoint [24] 0 0
Day 365
Secondary outcome [25] 0 0
Mahler Transitional Dyspnoea Index (TDI) Focal Score on Day 43 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)
Timepoint [25] 0 0
Day 43
Secondary outcome [26] 0 0
Mahler Transitional Dyspnoea Index (TDI) Focal Score on Day 85 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)
Timepoint [26] 0 0
Day 85
Secondary outcome [27] 0 0
Mahler Transitional Dyspnoea Index (TDI) Focal Score on Day 365 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)
Timepoint [27] 0 0
Day 365

Eligibility
Key inclusion criteria
Inclusion criteria:

1. Diagnosis of chronic obstructive pulmonary disease.
2. Relatively stable airway obstruction with post FEV1< 80% predicted normal and post FEV1/FVC <70%.
3. Male or female patients, 40 years of age or older.
4. Smoking history of more than 10 pack years.
Minimum age
40 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:

1. Significant disease other than COPD
2. Clinically relevant abnormal lab values.
3. History of asthma.
4. Diagnosis of thyrotoxicosis
5. Diagnosis of paroxysmal tachycardia
6. History of myocardial infarction within 1 year of screening visit
7. Unstable or life-threatening cardiac arrhythmia.
8. Hospitalization for heart failure within the past year.
9. Known active tuberculosis.
10. Malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years
11. History of life-threatening pulmonary obstruction.
12. History of cystic fibrosis.
13. Clinically evident bronchiectasis.
14. History of significant alcohol or drug abuse.
15. Thoracotomy with pulmonary resection
16. Oral ß-adrenergics.
17. Oral corticosteroid medication at unstable doses
18. Regular use of daytime oxygen therapy for more than one hour per day
19. Pulmonary rehabilitation program in the six weeks prior to the screening visit
20. Investigational drug within one month or six half lives (whichever is greater) prior to screening visit
21. Known hypersensitivity to ß-adrenergic drugs, anticholinergics, BAC, EDTA
22. Pregnant or nursing women.
23. Women of childbearing potential not using a highly effective method of birth control
24. Patients who are unable to comply with pulmonary medication restrictions

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/09/2011
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/11/2013
Sample size
Target
Accrual to date
Final
2539
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Idaho
Country [7] 0 0
United States of America
State/province [7] 0 0
Louisiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Maryland
Country [9] 0 0
United States of America
State/province [9] 0 0
Massachusetts
Country [10] 0 0
United States of America
State/province [10] 0 0
Minnesota
Country [11] 0 0
United States of America
State/province [11] 0 0
Missouri
Country [12] 0 0
United States of America
State/province [12] 0 0
Nevada
Country [13] 0 0
United States of America
State/province [13] 0 0
New Jersey
Country [14] 0 0
United States of America
State/province [14] 0 0
New Mexico
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
North Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Ohio
Country [18] 0 0
United States of America
State/province [18] 0 0
Oklahoma
Country [19] 0 0
United States of America
State/province [19] 0 0
Pennsylvania
Country [20] 0 0
United States of America
State/province [20] 0 0
Rhode Island
Country [21] 0 0
United States of America
State/province [21] 0 0
South Carolina
Country [22] 0 0
United States of America
State/province [22] 0 0
Texas
Country [23] 0 0
United States of America
State/province [23] 0 0
Virginia
Country [24] 0 0
United States of America
State/province [24] 0 0
Washington
Country [25] 0 0
Austria
State/province [25] 0 0
Feldbach
Country [26] 0 0
Austria
State/province [26] 0 0
Gänserndorf
Country [27] 0 0
Austria
State/province [27] 0 0
Innsbruck
Country [28] 0 0
Austria
State/province [28] 0 0
Leoben
Country [29] 0 0
Austria
State/province [29] 0 0
Linz
Country [30] 0 0
Austria
State/province [30] 0 0
Salzburg
Country [31] 0 0
Belgium
State/province [31] 0 0
Brussel
Country [32] 0 0
Belgium
State/province [32] 0 0
Bruxelles
Country [33] 0 0
Belgium
State/province [33] 0 0
Gent
Country [34] 0 0
Belgium
State/province [34] 0 0
Jambes
Country [35] 0 0
Belgium
State/province [35] 0 0
Lebbeke
Country [36] 0 0
Belgium
State/province [36] 0 0
Leuven
Country [37] 0 0
Belgium
State/province [37] 0 0
Liège
Country [38] 0 0
Belgium
State/province [38] 0 0
Oostende
Country [39] 0 0
Belgium
State/province [39] 0 0
Turnhout
Country [40] 0 0
Brazil
State/province [40] 0 0
Botucatu
Country [41] 0 0
Brazil
State/province [41] 0 0
Florianopolis
Country [42] 0 0
Brazil
State/province [42] 0 0
Passo Fundo
Country [43] 0 0
Brazil
State/province [43] 0 0
Porto Alegre
Country [44] 0 0
Brazil
State/province [44] 0 0
Sao Paulo
Country [45] 0 0
Canada
State/province [45] 0 0
Alberta
Country [46] 0 0
Canada
State/province [46] 0 0
British Columbia
Country [47] 0 0
Canada
State/province [47] 0 0
New Brunswick
Country [48] 0 0
Canada
State/province [48] 0 0
Ontario
Country [49] 0 0
Canada
State/province [49] 0 0
Quebec
Country [50] 0 0
China
State/province [50] 0 0
Baotou
Country [51] 0 0
China
State/province [51] 0 0
Beijing
Country [52] 0 0
China
State/province [52] 0 0
Changsha
Country [53] 0 0
China
State/province [53] 0 0
Chengdu
Country [54] 0 0
China
State/province [54] 0 0
Chongqing
Country [55] 0 0
China
State/province [55] 0 0
Haikou
Country [56] 0 0
China
State/province [56] 0 0
Hangzhou
Country [57] 0 0
China
State/province [57] 0 0
Hohhot
Country [58] 0 0
China
State/province [58] 0 0
Jinan
Country [59] 0 0
China
State/province [59] 0 0
Nanjing
Country [60] 0 0
China
State/province [60] 0 0
Shanghai
Country [61] 0 0
China
State/province [61] 0 0
Shenyang
Country [62] 0 0
China
State/province [62] 0 0
Suzhou
Country [63] 0 0
China
State/province [63] 0 0
Xi'An
Country [64] 0 0
Colombia
State/province [64] 0 0
Bogota DC
Country [65] 0 0
Colombia
State/province [65] 0 0
Bogota
Country [66] 0 0
Colombia
State/province [66] 0 0
Cali
Country [67] 0 0
Colombia
State/province [67] 0 0
Floridablanca
Country [68] 0 0
Croatia
State/province [68] 0 0
Petrinja
Country [69] 0 0
Croatia
State/province [69] 0 0
Rijeka
Country [70] 0 0
Croatia
State/province [70] 0 0
Zadar
Country [71] 0 0
Croatia
State/province [71] 0 0
Zagreb
Country [72] 0 0
Germany
State/province [72] 0 0
Aschaffenburg
Country [73] 0 0
Germany
State/province [73] 0 0
Berlin
Country [74] 0 0
Germany
State/province [74] 0 0
Frankfurt
Country [75] 0 0
Germany
State/province [75] 0 0
Großhansdorf
Country [76] 0 0
Germany
State/province [76] 0 0
Halle
Country [77] 0 0
Germany
State/province [77] 0 0
Hamburg
Country [78] 0 0
Germany
State/province [78] 0 0
Hannover
Country [79] 0 0
Germany
State/province [79] 0 0
Leipzig
Country [80] 0 0
Germany
State/province [80] 0 0
Mainz
Country [81] 0 0
Germany
State/province [81] 0 0
Rodgau/Dudenhofen
Country [82] 0 0
Germany
State/province [82] 0 0
Schwerin
Country [83] 0 0
Germany
State/province [83] 0 0
Teuchern
Country [84] 0 0
Hungary
State/province [84] 0 0
Debrecen
Country [85] 0 0
Hungary
State/province [85] 0 0
Gödöllö
Country [86] 0 0
Hungary
State/province [86] 0 0
Pecs
Country [87] 0 0
Hungary
State/province [87] 0 0
Sopron
Country [88] 0 0
Hungary
State/province [88] 0 0
Szeged
Country [89] 0 0
India
State/province [89] 0 0
Chennai
Country [90] 0 0
India
State/province [90] 0 0
Coimbatore
Country [91] 0 0
India
State/province [91] 0 0
Jaipur
Country [92] 0 0
India
State/province [92] 0 0
Kolkatta
Country [93] 0 0
India
State/province [93] 0 0
Maharastra
Country [94] 0 0
India
State/province [94] 0 0
Mumbai
Country [95] 0 0
India
State/province [95] 0 0
Nashik, Maharashtra
Country [96] 0 0
India
State/province [96] 0 0
Pune
Country [97] 0 0
Ireland
State/province [97] 0 0
County Limerick
Country [98] 0 0
Ireland
State/province [98] 0 0
Dublin 24
Country [99] 0 0
Ireland
State/province [99] 0 0
Dublin 4
Country [100] 0 0
Japan
State/province [100] 0 0
Abeno-ku, Osaka, Osaka
Country [101] 0 0
Japan
State/province [101] 0 0
Aoi-ku, Shizuoka, Shizuoka
Country [102] 0 0
Japan
State/province [102] 0 0
Chuo-ku, Kobe, Hyogo
Country [103] 0 0
Japan
State/province [103] 0 0
Fukui, Fukui
Country [104] 0 0
Japan
State/province [104] 0 0
Fukuyama, Hiroshima
Country [105] 0 0
Japan
State/province [105] 0 0
Hachioji, Tokyo
Country [106] 0 0
Japan
State/province [106] 0 0
Himeji, Hyogo
Country [107] 0 0
Japan
State/province [107] 0 0
Hitachi, Ibaraki
Country [108] 0 0
Japan
State/province [108] 0 0
Iizuka, Fukuoka
Country [109] 0 0
Japan
State/province [109] 0 0
Iwamizawa, Hokkaido
Country [110] 0 0
Japan
State/province [110] 0 0
Kamakura, Kanagawa
Country [111] 0 0
Japan
State/province [111] 0 0
Kanazawa, Ishikawa
Country [112] 0 0
Japan
State/province [112] 0 0
Kanazawa, Yokohama, Kanagawa
Country [113] 0 0
Japan
State/province [113] 0 0
Kashiwa, Chiba
Country [114] 0 0
Japan
State/province [114] 0 0
Kawasaki-ku, Kawasaki, Kanagawa
Country [115] 0 0
Japan
State/province [115] 0 0
Kita-ku, Okayama, Okayama
Country [116] 0 0
Japan
State/province [116] 0 0
Kita-ku, Sakai, Osaka
Country [117] 0 0
Japan
State/province [117] 0 0
Kita-ku, Sapporo, Hokkaido
Country [118] 0 0
Japan
State/province [118] 0 0
Kurashiki, Okayama
Country [119] 0 0
Japan
State/province [119] 0 0
Minami-ku, Yokohama, Kanagawa
Country [120] 0 0
Japan
State/province [120] 0 0
Mitaka, Tokyo
Country [121] 0 0
Japan
State/province [121] 0 0
Mito, Ibaraki
Country [122] 0 0
Japan
State/province [122] 0 0
Naha, Okinawa
Country [123] 0 0
Japan
State/province [123] 0 0
Nishi-ku, Kobe, Hyogo
Country [124] 0 0
Japan
State/province [124] 0 0
Obihiro, Hokkaido
Country [125] 0 0
Japan
State/province [125] 0 0
Okinawa, Okinawa
Country [126] 0 0
Japan
State/province [126] 0 0
Ota-ku, Tokyo
Country [127] 0 0
Japan
State/province [127] 0 0
Sakaide, Kagawa
Country [128] 0 0
Japan
State/province [128] 0 0
Sapporo, Hokkaido
Country [129] 0 0
Japan
State/province [129] 0 0
Shimajiri-gun, Okinawa
Country [130] 0 0
Japan
State/province [130] 0 0
Shinjuku-ku, Tokyo
Country [131] 0 0
Japan
State/province [131] 0 0
Soka, Saitama
Country [132] 0 0
Japan
State/province [132] 0 0
Takarazuka, Hyogo
Country [133] 0 0
Japan
State/province [133] 0 0
Takayama, Gifu
Country [134] 0 0
Japan
State/province [134] 0 0
Tomigusuku, Okinawa
Country [135] 0 0
Japan
State/province [135] 0 0
Toyonaka, Osaka
Country [136] 0 0
Japan
State/province [136] 0 0
Uji, Kyoto
Country [137] 0 0
Japan
State/province [137] 0 0
Yabu, Hyogo
Country [138] 0 0
Japan
State/province [138] 0 0
Yao, Osaka
Country [139] 0 0
Japan
State/province [139] 0 0
Yokosuka, Kanagawa
Country [140] 0 0
Norway
State/province [140] 0 0
Elverum
Country [141] 0 0
Norway
State/province [141] 0 0
Hønefoss
Country [142] 0 0
Norway
State/province [142] 0 0
Kløfta
Country [143] 0 0
Norway
State/province [143] 0 0
Lierskogen
Country [144] 0 0
Norway
State/province [144] 0 0
Oslo
Country [145] 0 0
Norway
State/province [145] 0 0
SKI
Country [146] 0 0
Norway
State/province [146] 0 0
Svelvik
Country [147] 0 0
Romania
State/province [147] 0 0
Arad
Country [148] 0 0
Romania
State/province [148] 0 0
Bucharest
Country [149] 0 0
Romania
State/province [149] 0 0
Bucuresti
Country [150] 0 0
Romania
State/province [150] 0 0
Cluj
Country [151] 0 0
Russian Federation
State/province [151] 0 0
Moscow
Country [152] 0 0
Russian Federation
State/province [152] 0 0
St. Petersburg
Country [153] 0 0
Russian Federation
State/province [153] 0 0
Yaroslavl
Country [154] 0 0
Serbia
State/province [154] 0 0
Belgrade
Country [155] 0 0
Serbia
State/province [155] 0 0
Kragujevac
Country [156] 0 0
Serbia
State/province [156] 0 0
Nis
Country [157] 0 0
Slovakia
State/province [157] 0 0
Bardejov
Country [158] 0 0
Slovakia
State/province [158] 0 0
Bojnice
Country [159] 0 0
Slovakia
State/province [159] 0 0
Kosice
Country [160] 0 0
Slovakia
State/province [160] 0 0
Nitra
Country [161] 0 0
Slovakia
State/province [161] 0 0
Spisska Nova Ves
Country [162] 0 0
Slovakia
State/province [162] 0 0
Zilina
Country [163] 0 0
South Africa
State/province [163] 0 0
Bellville
Country [164] 0 0
South Africa
State/province [164] 0 0
Cape Town
Country [165] 0 0
South Africa
State/province [165] 0 0
Pretoria
Country [166] 0 0
Spain
State/province [166] 0 0
Badalona (Barcelona)
Country [167] 0 0
Spain
State/province [167] 0 0
Barcelona
Country [168] 0 0
Spain
State/province [168] 0 0
Hospitalet de Llobregat
Country [169] 0 0
Spain
State/province [169] 0 0
Mérida
Country [170] 0 0
Spain
State/province [170] 0 0
Pozuelo de Alarcón
Country [171] 0 0
Spain
State/province [171] 0 0
San Juan de Alicante
Country [172] 0 0
Spain
State/province [172] 0 0
Vic (Barcelona)
Country [173] 0 0
Sweden
State/province [173] 0 0
Boden
Country [174] 0 0
Sweden
State/province [174] 0 0
Göteborg
Country [175] 0 0
Sweden
State/province [175] 0 0
Härnösand
Country [176] 0 0
Sweden
State/province [176] 0 0
Höllviken
Country [177] 0 0
Sweden
State/province [177] 0 0
Lund
Country [178] 0 0
Sweden
State/province [178] 0 0
Stockholm
Country [179] 0 0
Sweden
State/province [179] 0 0
Uddevalla
Country [180] 0 0
Taiwan
State/province [180] 0 0
Kaohsiung City
Country [181] 0 0
Taiwan
State/province [181] 0 0
Kaohsiung
Country [182] 0 0
Taiwan
State/province [182] 0 0
New Taipei City
Country [183] 0 0
Taiwan
State/province [183] 0 0
Taichung
Country [184] 0 0
Taiwan
State/province [184] 0 0
Tainan
Country [185] 0 0
Taiwan
State/province [185] 0 0
Taipei
Country [186] 0 0
Taiwan
State/province [186] 0 0
Taoyuan County
Country [187] 0 0
Turkey
State/province [187] 0 0
Ankara
Country [188] 0 0
Turkey
State/province [188] 0 0
Denizli
Country [189] 0 0
Turkey
State/province [189] 0 0
Istanbul
Country [190] 0 0
Turkey
State/province [190] 0 0
Izmir
Country [191] 0 0
United Kingdom
State/province [191] 0 0
Blackpool
Country [192] 0 0
United Kingdom
State/province [192] 0 0
Bristol
Country [193] 0 0
United Kingdom
State/province [193] 0 0
Chertsey
Country [194] 0 0
United Kingdom
State/province [194] 0 0
Fleetwood
Country [195] 0 0
United Kingdom
State/province [195] 0 0
Manchester
Country [196] 0 0
United Kingdom
State/province [196] 0 0
Midsomer Norton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Boehringer Ingelheim
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The overall objective of this study is to assess the efficacy and safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the RESPIMAT Inhaler) compared with the individual components (tiotropium, olodaterol) (delivered by the RESPIMAT Inhaler) in patients with COPD.
Trial website
https://clinicaltrials.gov/study/NCT01431287
Trial related presentations / publications
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed

Contacts
Principal investigator
Name 0 0
Boehringer Ingelheim
Address 0 0
Boehringer Ingelheim
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01431287